Prime

Type your tag names separated by a space and hit enter

Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies.

Abstract

INTRODUCTION

CNS metastases mean a great challenge. It has been suggested that the brain metastases incidence could be high in metastasic breast cancer patients receiving trastuzumab based-therapies.

MATERIAL AND METHODS

We performed a descriptive analysis of our experience in this setting. 86 patients met the criteria (From Oct/99 to Oct/03).

RESULTS

CNS progression occurred in 17 patients (19.5%). Mean age of CNS progression disease patients was 45.4 years while mean age for all the patients was 50.5 years. Response rate for the entire group of patients was: OR 39.7%; CB (OR + SD) 69%. Response rate to trastuzumab based-therapy was OR 82.4% and CB 88.2 at the time of CNS progression. Median time from the start of trastuzumab therapy up to the CNS progression was 10 months. OS was 23.4 weeks.

CONCLUSIONS

The incidence of CNS involvement is high in young metastasic breast cancer women responding to trastuzumab-based therapies. This may lead to prophylactic cranial irradiation strategies or to the early detection in asymptomatic patients to improve surgery or radiosurgery results in these patients.

Authors+Show Affiliations

,

Servicio de Oncología Médica, Hospital Clínico San Carlos, Madrid, Spain. javierpuen@hotmail.com

, , , , , , , ,

Source

MeSH

Adenocarcinoma
Adult
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Brain Neoplasms
Breast Neoplasms
Carcinoma
Cranial Irradiation
Disease Progression
ErbB Receptors
Female
Humans
Incidence
Middle Aged
Neoplasm Proteins
Receptor, ErbB-4
Retrospective Studies
Survival Analysis
Trastuzumab
Treatment Outcome

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16632440

Citation

TY - JOUR T1 - Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies. AU - Puente Vázquez,Javier, AU - López-Tarruella Cobo,Sara, AU - García-Sáenz,José A, AU - Casado Herráez,Antonio, AU - Moreno Antón,Fernando, AU - Sampedro Gimeno,Teresa, AU - Bueno Muiño,Coralia, AU - Grande Pulido,Enrique, AU - Martín Jiménez,Miguel, AU - Díaz-Rubio,Eduardo, PY - 2006/4/25/pubmed PY - 2006/5/25/medline PY - 2006/4/25/entrez SP - 50 EP - 3 JF - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico JO - Clin Transl Oncol VL - 8 IS - 1 N2 - INTRODUCTION: CNS metastases mean a great challenge. It has been suggested that the brain metastases incidence could be high in metastasic breast cancer patients receiving trastuzumab based-therapies. MATERIAL AND METHODS: We performed a descriptive analysis of our experience in this setting. 86 patients met the criteria (From Oct/99 to Oct/03). RESULTS: CNS progression occurred in 17 patients (19.5%). Mean age of CNS progression disease patients was 45.4 years while mean age for all the patients was 50.5 years. Response rate for the entire group of patients was: OR 39.7%; CB (OR + SD) 69%. Response rate to trastuzumab based-therapy was OR 82.4% and CB 88.2 at the time of CNS progression. Median time from the start of trastuzumab therapy up to the CNS progression was 10 months. OS was 23.4 weeks. CONCLUSIONS: The incidence of CNS involvement is high in young metastasic breast cancer women responding to trastuzumab-based therapies. This may lead to prophylactic cranial irradiation strategies or to the early detection in asymptomatic patients to improve surgery or radiosurgery results in these patients. SN - 1699-048X UR - https://www.unboundmedicine.com/medline/citation/16632440/abstract/Brain_metastases_in_metastatic_breast_cancer_patients_receiving_trastuzumab_based_therapies L2 - http://www.diseaseinfosearch.org/result/960 ER -